Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Wallerfing – page 6

90 clinical trials in Wallerfing, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Wallerfing at a glance
90
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

90 trials in Wallerfing

Open in trial search

Marginal zone lymphoma+3

Not recruiting

Study of Obinutuzumab as First-Line Treatment for Adult Patients with Marginal Zone Lymphoma Who Are Not Eligible for Local Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Universitaetsklinikum Ulm AöR

Study on Copanlisib and Rituximab for Patients with Marginal Zone Lymphoma Needing Treatment After Local Therapy Failure or Relapse

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Universitaetsklinikum Ulm AöR

Hypertriglyceridaemia

Not recruiting

Study on Plozasiran and ARO-APOC3 for Adults with Severe Hypertriglyceridemia

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Adenocarcinoma gastric+1

Not recruiting

Study Comparing Ramucirumab with Irinotecan, Leucovorin, and 5-FU or Paclitaxel for Patients with Advanced Stomach or Gastroesophageal Cancer After Previous Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Acute myeloid leukaemia+1

Not recruiting

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enasidenib Mesilate
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Bronchitis

Not recruiting

Study on the Effectiveness of Thyme Herb Extract, Primrose Root Tincture, and Ivy Leaf Extract for Patients with Acute Bronchitis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Engelhard Arzneimittel GmbH & Co. KG

Study Comparing Standard Chemotherapy with CPX-351 for Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) and Intermediate or Adverse Genetics

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Universitaetsklinikum Ulm AöR

Hypertension

Not recruiting

Study on Baxdrostat for Reducing Blood Pressure in Patients with Uncontrolled or Resistant Hypertension

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:AstraZeneca AB

Colon cancer stage II+1

Not recruiting

Study on Adjuvant Therapy with Capecitabine for Stage II Colon and Rectal Cancer Patients with Positive ctDNA After Tumor Removal

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Technische Universitat Dresden

Study on Acalabrutinib for Very Old or Frail Patients with Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:University Of Cologne

Study on Mavacamten for Adults with Non-obstructive Hypertrophic Cardiomyopathy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Mavacamten
  • Sponsor:Myokardia Inc.

Other cities in Germany

The busiest research cities in the country

All 503 cities in Germany

Clinical research in Wallerfing

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on atherosclerotic cardiovascular disease and heart conditions, evaluating new treatments for reducing major adverse cardiovascular events and managing heart failure.

  • ASCVD Management
  • Heart Failure Treatment
  • Cardiovascular Risk Reduction

Research includes novel therapies combining established medications with experimental compounds.

02 Metabolic Disorders

Comprehensive trials examining treatments for hypertriglyceridemia and metabolic conditions, including studies on obesity and type 2 diabetes management.

  • Triglyceride Level Control
  • Weight Management
  • Diabetes Treatment

Multiple approaches to metabolic health improvement through innovative therapeutic solutions.

03 Respiratory Medicine

Advanced research into respiratory syncytial virus infections and COPD, including vaccine development and treatment optimization studies.

  • RSV Vaccination
  • COPD Management
  • Bronchitis Treatment

Focus on both preventive measures and therapeutic interventions for respiratory conditions.

04 Dermatological Studies

Clinical investigations of treatments for various skin conditions, including papulopustular rosacea and fungal infections.

  • Skin Infection Treatment
  • Rosacea Management
  • Acne Therapy

Evaluation of topical treatments and their comparative efficacy.

05 Gastrointestinal Research

Studies examining treatments for functional gastrointestinal disorders, with particular focus on irritable bowel syndrome.

  • IBS Management
  • Digestive Health
  • Gut Function

Investigation of both conventional and herbal therapeutic approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.